Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTRB1 | P17538 | 5/20 | 0.59 |
| ▸ | LTA4H | P09960 | 1/20 | 0.54 |
| ▸ | ANPEP | P15144 | 1/20 | 0.54 |
| ▸ | CA1 | P00915 | 2/20 | 0.48 |
| ▸ | CA2 | P00918 | 2/20 | 0.48 |
| ▸ | TAAR1 | Q96RJ0 | 1/20 | 0.47 |
| ▸ | FPR2 | P25090 | 1/20 | 0.46 |
| ▸ | NAALAD2 | Q9Y3Q0 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 2/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.44 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | ATM | Q13315 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL31656407 | 1.00 | CTRB1 (0.59) | CTRB1LTA4HANPEPCA1CA2 | |
| SCHEMBL29697050 | 0.94 | CTRB1 (0.54) | CTRB1LTA4HANPEPCA1CA2 | |
| SCHEMBL2961809 | 0.88 | CTRB1 (0.58) | CTRB1LTA4HANPEPTAAR1LMNA | |
| SCHEMBL11354701 | 0.86 | FOLH1 (0.55) | CTRB1LTA4HANPEPNAALAD2KMT2A | |
| SCHEMBL11354402 | 0.86 | FOLH1 (0.55) | CTRB1LTA4HANPEPNAALAD2KMT2A | |
| SCHEMBL12864508 | 0.85 | LTA4H (0.56) | LTA4HANPEPCA1CA2FPR2 | |
| SCHEMBL8310215 | 0.85 | LTA4H (0.56) | LTA4HANPEPCA1CA2FPR2 | |
| Bromide SCHEMBL11351543 | 0.85 | FOLH1 (0.54) | CTRB1LTA4HANPEPNAALAD2KMT2A | |
| Bromide SCHEMBL11346347 | 0.85 | FOLH1 (0.54) | CTRB1LTA4HANPEPNAALAD2KMT2A | |
| SCHEMBL2184423 | 0.84 | CA1 (0.49) | CTRB1LTA4HANPEPCA1CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8334266-B2 | Process for and intermediates in the preparation of canfosfamide and its salts | TELIK, INC. (US) | 2012-12-18 | — | — | US | disclosed |
| US-20120238772-A1 | PROCESS FOR AND INTERMEDIATES IN THE PREPARATION OF CANFOSFAMIDE AND ITS SALTS | TELIK, INC. | 2012-09-20 | — | — | US | disclosed |
| US-8198247-B2 | Process for and intermediates in the preparation of canfosfamide and its salts | TELIK, INC. (US) | 2012-06-12 | — | — | US | disclosed |
| US-7655799-B2 | 2{[2-(substituted amino)ethyl]sulfonyl}ethyl N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates | TELIK, INC. (US) | 2010-02-02 | — | — | US | disclosed |
| US-20080125398-A1 | 2-ETHYL N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates | TELIK, INC. | 2008-05-29 | — | — | US | disclosed |
| US-20060135409-A1 | Process for and intermediates in the preparation of canfosfamide and its salts | TELIK, INC. | 2006-06-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060135409-A1 | Process for and intermediates in the preparation of canfosfamide and its salts | WEE1, WEE2, TYMP | CTRB1 3912/4885LTA4H 4193/4885ANPEP 918/4885 |
| US-20080125398-A1 | 2-ETHYL N,N,N',N'-tetrakis(2-chloroethyl)phosphorodiamidates | NCL, NEK2, NME2 | CTRB1 4389/4885LTA4H 4525/4885ANPEP 128/4885 |
| US-20120238772-A1 | PROCESS FOR AND INTERMEDIATES IN THE PREPARATION OF CANFOSFAMIDE AND ITS SALTS | WEE1, WEE2, TYMP | CTRB1 3912/4885LTA4H 4193/4885ANPEP 918/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.